Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
Monica VerdoiaH SuryapranataS DamenC CamaroE BenitL BarbieriS RasoulH B LiewJ PoladW A W AhmadR ZambahariJ LalmandR J van der SchaafT H KohP TimmermansD Dilling-BoerL F VeenstraA W J Van't HofS W L LeeV RoolvinkE LigtenbergS PostmaE J J KolkmanM A BrouwerE KedhiG De LucaPublished in: Journal of thrombosis and thrombolysis (2021)
The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 2-years follow-up in both male and female gender.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- phase iii
- percutaneous coronary intervention
- phase ii
- newly diagnosed
- end stage renal disease
- clinical trial
- study protocol
- open label
- ejection fraction
- double blind
- chronic kidney disease
- placebo controlled
- mental health
- prognostic factors
- randomized controlled trial
- mesenchymal stem cells
- bone marrow
- patient reported